Immunotherapy for malignant melanoma with a tumor cell vaccine.
Specific active immunotherapy for melanoma has been administered to several thousand patients since 1972, using an irradiated whole-cell preparation. A humoral response to vaccination can be demonstrated in a large percentage of patients. This response increases while immunizations are continued and decreases after cessation of therapy. The vaccinations are well tolerated; however, the therapeutic impact of this whole-cell vaccine awaits a randomized trial for definitive evaluation.
Slingluff
C L
CL
Department of Surgery, Duke University Medical Center, Durham, NC.
Seigler
H F
HF
D000046:Academic Medical Centers; D000951:Antigens, Neoplasm; D001500:BCG Vaccine / Q000276:immunology / Q000592:standards / Q000627:therapeutic use*; D002985:Clinical Protocols / Q000592:standards; D003429:Cross Reactions; D004341:Drug Evaluation; D005500:Follow-Up Studies; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods / Q000592:standards*; D008545:Melanoma / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins / Q000276:immunology; D009657:North Carolina / Q000453:epidemiology; D012878:Skin Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D006680:HLA Antigens; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins